TransMedics Group Inc. (TMDX)
Why Transmedics Plunged in December
Shares of Transmedics (TMDX 9.47%) fell 28.1% in December, according to data from S&P Global Market Intelligence.
Buying The Dip: How TransMedics Is Set To Soar In A Potential $23 Billion Market
Buying The Dip: How TransMedics Is Set To Soar In A Potential $23 Billion Market
1 Super Growth Stock Down 63% to Buy Hand Over Fist in 2025
Leading organ transplant technology provider TransMedics (TMDX 3.90%) increased sales by more than 100% in 10 straight quarters from early 2022 to mid-2024. However, after delivering revenue growth of "only" 64% in its latest quarter -- while lowering guidance for a 35% increase in the upcoming fourth quarter -- the company has seen its stock plummet roughly 63% from its highs.
Breaking Into Healthcare: Why TransMedics Is My Bold First Move
TransMedics is transforming organ transplants with advanced technology and integrated logistics. Strong market demand and expanding adoption support long-term growth potential despite the recent top-line deceleration. Following the recent nosedive, the stock's current valuation offers an attractive entry point for a market leader in a critical industry.
TransMedics Stock Plunges 57.5% in Three Months: What's Next?
TMDX is enhancing its current focus on making meaningful progress across each of its growth initiatives. However, macro challenges are likely to hurt its performance.
Is TransMedics Stock a Buy Before 2025?
In today's video, I will discuss recent updates about TransMedics (TMDX -2.36%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
Down Over 60%, Is TransMedics Stock a Buy on the Dip?
TransMedics Group (TMDX 3.03%) was a top-performing stock that more than doubled in value during the months between the end of 2023 and late August.
Why Transmedics Group Stock Plummeted 21% This Week
Shares of Transmedics Group (TMDX 2.13%) sank over 20% this week, according to data from S&P Global Market Intelligence. The organ transplant disrupter announced a CFO transition and reduced the range for its full-year 2024 guidance, indicating slowing revenue growth.
TransMedics: A Look At What Is Behind The Loss Of Sales Momentum In H2 2024
TransMedics shares declined 60% from their August peak after a Q3 revenue miss, and more recently by slightly reduced revenue guidance range, surprising investors accustomed to beat-and-raise guidance. The company faces near-term challenges, but long-term growth prospects remain strong. The CEO suggested a temporary pause in growth at the Piper Sandler conference this week, with stronger performance expected in 2H 2025, driven by clinical data from heart and lung programs.
Why TransMedics Stock Plummeted Today
Shares of leading organ transplant platform TransMedics (TMDX -15.43%) were down 14% as of noon ET on Wednesday, according to data provided by S&P Global Market Intelligence.
Is TMDX Stock a Buy, Sell or Hold at a P/S Multiple of 5.02X?
TransMedics is facing a softness in demand for transplant services in the United States. Moreover, rising costs raise concern.
1 Top Growth Stock Down 56% to Buy After Its Recent Pullback
In this video, I will talk about recent updates regarding TransMedics (TMDX 3.34%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
